Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1992-8-14
pubmed:abstractText
Chiralpak AD is a commercially available high-performance liquid chromatographic column containing a chiral stationary phase composed of 3,5-dimethylphenylcarbamate-derivatized amylose coated on silica. This column was applied to the assay for the plasma concentrations of the enantiomers of verapamil and its major metabolite norverapamil. After the extraction from plasma, the analytes were separated on a diol silica column (LiChrocart DIOL) and Chiralpak AD column which were connected in series in this order and detected using a fluorescence detector (excitation at 272 nm, emission at 317 nm). The enantiomers of verapamil and norverapamil were separated from each other and other metabolites using a mobile phase of hexane-isopropanol-ethanol (85:7.5:7.5, v/v/v) containing 1.0% triethylamine. The calibration curves were linear (R greater than 0.9989) in the plasma concentration range 2.5-100 ng/ml for verapamil enantiomers and 5.0-100 ng/ml for norverapamil enantiomers. The intra-day and inter-day reproducibility tests showed good reproducibilities; coefficients of variation of each enantiomer were less than 14.9% at the lowest concentration and less than 2.0% at the highest concentration. The effect of organic modifier content and column temperature upon the retention and the enantioseparation were also discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0021-9673
pubmed:author
pubmed:issnType
Print
pubmed:day
7
pubmed:volume
574
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
85-92
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Simultaneous direct determination of the enantiomers of verapamil and norverapamil in plasma using a derivatized amylose high-performance liquid chromatographic chiral stationary phase.
pubmed:affiliation
Department of Oncology, McGill University, Montreal, Quebec, Canada.
pubmed:publicationType
Journal Article